Azacitidine and decitabine belong to a class of antineoplastic agents known as DNA methyltransferase inhibitors (DMTIs). Each is paired with cedazuridine, a cytidine deaminase inhibitor, to help the ...
The combination of decitabine/cedazuridine and venetoclax achieved a 91% overall response rate in HR-MDS and CMML patients, with early responses observed. Median overall survival reached 30 months, ...
A decade-long investigation of shorter regimens of hypomethylating agents for low-risk myelodysplastic syndrome revealed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results